Read Comment and Support Letters
Medicare Drug Price Negotiation Program
Comment Letter | June 25, 2024
Race and Ethnicity Data Collection in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
Comment Letter | April 29, 2024
Request for Information on Reauthorization of the Older Americans Act – US Senate HELP Committee
Comment Letter | March 21, 2024
Request for Information on Gene Therapy Access – US Senate HELP Committee
Comment Letter | January 22, 2024
Statement on the UN General Assembly Zero-Draft Resolution of the “Scope, modalities, format and organization of the High-Level Meeting on Antimicrobial Resistance convened by the President of the General Assembly”
Comment Letter | January 18, 2024
Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act Reintroduction
Letter of Support | September 22, 2023
Implementation of California’s Master Plan for Aging
Comment Letter | August 24, 2023
FDA Draft Guidance on Decentralized Clinical Trials for Drugs, Biological Products, and Devices
Comment Letter | July 31, 2023
Request for Information on implementation of the Community Disaster Resilience Zones Act of 2022
Comment Letter | July 25, 2023
Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Discussion Draft - US Senate HELP Committee
Comment Letter | July 10, 2023
Digital Asset Market Structure Discussion Draft
Comment Letter | June 13, 2023
Advancing Clinical and Translational Science through Accelerating the Decentralization of Clinical Trials
Comment Letter | May 12, 2023
Statement at Multi-Stakeholder meeting in support of the UN High-Level Meeting on Pandemic Prevention, Preparedness and Response
Comment Letter | May 9, 2023
Expiration of the Public Health Emergency for COVID-19
Comment Letter | April 19, 2023
Medicare Drug Price Negotiation Program Guidance
Comment Letter | April 14, 2023
Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization – US Senate HELP Committee
Comment Letter | March 29, 2023
Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization – US House Energy & Commerce Committee
Comment Letter | March 13, 2023
OSTP RFI on Clinical Research Infrastructure and Emergency Clinical Trials
Comment Letter | December 27, 2022
Patient Perspectives on Gene Therapy Products
Comment Letter | December 15, 2022
End of Year Legislative Package – Retirement Security Provisions
Letter of Support | December 12, 2022
Environmental Protection Agency Greenhouse Gas Reduction Fund
Comment Letter | December 5, 2022
End of Year Legislative Package – Health Provisions
Letter of Support | December 1, 2022
Reauthorization of Food and Drug Administration (FDA) User Fee Programs
Letter of Support | September 7, 2022
Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act)
Letter of Support | August 2, 2022
The White House Conference on Hunger, Nutrition, and Health
Comment Letter | July 11, 2022
2023-2026 National Health Security Strategy (NHSS)
Letter of Support | March 11, 2022
Municipal Securities Rulemaking Board (MRSB) on ESG
Comment Letter | March 8, 2022
Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Decision
Comment Letter | February 9, 2022
Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Draft Legislation
Comment Letter | February 4, 2022
Prescription Drug User Fee Act VII (PDUFA)
Comment Letter | October 28, 2021
Financial Industry Regulatory Authority (FINRA) Short Sale Disclosures
Comment Letter | September 29, 2021
Advanced Research Projects Agency for Health (ARPA-H) Request for Information
Comment Letter | July 16, 2021
Office of Management and Budget (OMB) – Practices for Advancing Equity and Support for Underserved Communities
Comment Letter | July 6, 2021
Food and Drug Administration (FDA) – Medical Device User Fee Act (MDUFA)
Comment Letter | November 25, 2020
Advancing Connectivity during the Coronavirus to Ensure Support for Seniors (ACCESS) Act, S.3517
Letter of Support | May 20, 2020
Department of Transportation (DOT) – Regional Infrastructure Accelerator Program
Comment Letter | March 25, 2020
Request for Information Regarding Tech Sprints
Comment Letter | December 2, 2019
Internal Revenue Service Request for Comment Regarding the Opportunity Zone Proposed Regulations
Comment Letter | March 27, 2019
Policy on No-Action Letters and the Consumer Financial Protection Bureau (CFPB) Product Sandbox
Comment Letter | February 26, 2017
Small Business Administration (SBA) on Regulatory Burden Docket
Comment Letter | November 15, 2017
Alternative Data and Modeling Techniques in the Credit Process
Comment Letter | May 19, 2017
Licensing Manual Draft Supplement on Evaluating Charter Applications from FinTech Companies
Comment Letter | April 10, 2017
Special Purpose National Bank Charters for FinTech Companies
Comment Letter | January 15, 2017
Proposed Guidance for Third-Party Lending
Comment Letter | October 27, 2016
Comments on the Department of the Treasury Notice: Public Input on Expanding Access to Credit Through Online Marketplace Lending
Comment Letter | September 28, 2015